NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
Revolution Medicines, Inc.
University Medical Center Groningen
Institut Mutualiste Montsouris
CritiTech, Inc.